Old and new aldosteron antagonists in everyday clinical practice – the duel Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2019
Keywords:
eplerenone, spironolactone, heart failure, hypertension

Main Article Content

Radosław Grabysa
I Oddział Chorób Wewnętrznych i Gastroenterologii, Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie

Abstract

The paper presents the short characteristics of currently used aldosterone antagonists, which may help in the selection of a drug in a particular clinical situation.

Downloads

Download data is not yet available.

Article Details

How to Cite
Grabysa , R. (2019). Old and new aldosteron antagonists in everyday clinical practice – the duel. Cardiology in Practice, 13(3-4), 24-27. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1186
Issue
Vol 13 No 3-4 (2019)
Section
Pharmacology in cardiological practice
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Ponikowski P., Voors A.A., Anker S.D. et al.: Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol. Pol. 2016; 74(10): 1037-1147.
2. Pitt B., Zannad F., Remme W.J. et al.: Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
3. Zannad F., McMurray J.J.V., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
4. Kapłon-Cieślicka A., Filipiak K.J.: Eplerenon – co wiadomo o tym leku na początku 2009 roku? Choroby Serca i Naczyń 2009; 6(1): 26-36.
5. Pitt B., Remme W., Zannad F. et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
6. Swedberg K., Zannad F., McMurray J.J. et al.: Eplerenone and atrial fibrillation in mild heart failure: results from the EMPHASIS-HF study. J. Am. Coll. Cardiol. 2012; 59: 1598-1603.
7. Liu T., Korantzopoulos P., Shao Q. et al.: Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. EP Europace 2016; 5: 672-678.
8. Tykarski A., Filipiak K.J., Januszewicz A. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś. Tęt. 2019; 23: 41-87.